DMD and Duchenne muscular dystrophy: The finding that dystrophin-deficient satellite cells are intrinsically defective suggest that therapies enhancing satellite cell myogenic capacity have the potential to improve muscle regeneration and ameliorate the quality of life of DMD patients (Figure 3).